Dimension (DMTX) Alert: Johnson Fistel Investigates Proposed Sale of Dimension Therapeutics, Inc.; Are Shareholders Getting a Fair Price?

SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dimension Therapeutics, Inc. (NASDAQ: DMTX) ("Dimension") breached their fiduciary duties in connection with the proposed sale of the Company to Ultragenyx Pharmaceutical Inc.

On October 3, 2017, Dimension announced that it had signed a definitive merger agreement with Ultragenyx. Terms of the deal call for shareholders to receive $6.00 per share for each share of Dimension stock they own.

The investigation concerns whether the Dimension board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Dimension shares of common stock.

If you are a shareholder of Dimension and believe the proposed buyout price is too low or you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP

Jim Baker, 619-814-4471

jimb@johnsonfistel.com

View original content:http://www.prnewswire.com/news-releases/dimension-dmtx-alert-johnson-fistel-investigates-proposed-sale-of-dimension-therapeutics-inc-are-shareholders-getting-a-fair-price-300529946.html

SOURCE Johnson Fistel, LLP